Trial Profile
A Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients With Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Chondrosarcoma; Soft tissue sarcoma; Solitary-fibrous-tumour
- Focus Therapeutic Use
- 24 Mar 2023 Status changed to completed.
- 31 Jan 2022 Planned End Date changed from 31 Dec 2021 to 30 Jun 2022.
- 28 Jul 2021 Planned End Date changed from 1 Jun 2021 to 31 Dec 2021.